Posted by Michael Wonder on 05 Jul 2016
TGA publishes AusPAR for emtricitabine with elvitegravir and cobicistat and tenofovir alafenamide fumarate (Genvoya)
5 July 2016 - The TGA has published an AusPAR for Gilead's Genvoya.
The TGA approved the use of emtricitabine with elvitegravir and cobicistat and tenofovir alafenamide fumarate (Genvoya) as a single tablet regimen for the treatment of HIV-1 infection in adults and adolescents aged 12 years of age and older with body weight at least 35 kg who are either treatment, naive; or virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen on 12 January 2016.
